MCID: DCT002
MIFTS: 59

Ductal Carcinoma in Situ

Categories: Cancer diseases

Aliases & Classifications for Ductal Carcinoma in Situ

MalaCards integrated aliases for Ductal Carcinoma in Situ:

Name: Ductal Carcinoma in Situ 12 29 15
Noninfiltrating Intraductal Carcinoma 71

Classifications:



External Ids:

Disease Ontology 12 DOID:0060074
UMLS 71 C0007124

Summaries for Ductal Carcinoma in Situ

Disease Ontology : 12 A breast carcinoma in situ that is characterized by being non-invasive, not having spread outside of the duct into the surrounding breast tissue, has material basis in abnormally proliferating cells, derives from epithelial cells.

MalaCards based summary : Ductal Carcinoma in Situ, also known as noninfiltrating intraductal carcinoma, is related to comedo carcinoma and gynecomastia. An important gene associated with Ductal Carcinoma in Situ is AKT1 (AKT Serine/Threonine Kinase 1), and among its related pathways/superpathways are ERK Signaling and GPCR Pathway. The drugs Letrozole and mometasone furoate have been mentioned in the context of this disorder. Affiliated tissues include breast, lymph node and skin, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 74 Ductal carcinoma in situ (DCIS), also known as intraductal carcinoma, is a pre-cancerous or non-invasive... more...

Related Diseases for Ductal Carcinoma in Situ

Diseases related to Ductal Carcinoma in Situ via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 480)
# Related Disease Score Top Affiliating Genes
1 comedo carcinoma 33.7 TP53 PGR KRT14 ESR1 ERBB2
2 gynecomastia 31.6 PGR ESR1 ERBB2 CYP19A1
3 mammary paget's disease 31.5 PGR KRT14 ESR1 ERBB2 EGFR
4 lobular neoplasia 31.5 TP53 PGR KRT5 ESR1 ERBB2 CDH1
5 mammographic density 31.5 PGR ESR1 CYP19A1
6 breast fibroadenoma 31.5 TP53 PGR KRT14 ESR1 ERBB2 CYP19A1
7 squamous cell papilloma 31.4 TP53 KRT14
8 tubular adenocarcinoma 31.4 PGR ESR1 ERBB2 EGFR CDH1
9 intraductal papilloma 31.3 PGR KRT5 KRT14 ESR1 ERBB2 CD44
10 papillary carcinoma 31.3 PGR ESR1 ERBB2 CDH1 CD44
11 in situ carcinoma 31.2 TP53 S100A7 PGR MIR17 KRT5 KRT14
12 papilloma 31.0 TP53 PTGS2 KRT5 KRT14 ESR1 EGFR
13 female breast cancer 31.0 TP53 PGR ESR1 ERBB2 CYP19A1 BRCA2
14 adenoma 31.0 TP53 PTGS2 CDKN2A CDH1 CCND1
15 breast ductal carcinoma 30.9 TP53 S100A7 PGR MIR17 KRT5 KRT14
16 estrogen excess 30.9 PGR ESR1 CYP19A1
17 vaginal discharge 30.9 PGR ESR1 CYP19A1
18 microglandular adenosis 30.9 TP53 PGR ESR1 ERBB2 EGFR CDH1
19 spindle cell carcinoma 30.8 PGR KRT5 KRT14 ESR1 CDH1
20 exanthem 30.8 ERBB2 EGFR AKT1
21 bilateral breast cancer 30.8 PGR ESR1 ERBB2 CDKN2A CDH1 BRCA2
22 papillary serous adenocarcinoma 30.8 TP53 PGR BRCA2 BRCA1
23 insulin-like growth factor i 30.8 ESR1 EGFR EGF AKT1
24 pleomorphic carcinoma 30.8 TP53 PGR KRT14 EGFR
25 cribriform carcinoma 30.8 PGR KRT5 ESR1 ERBB2
26 breast disease 30.8 TP53 PGR MIR17 KRT5 ESR1 ERBB2
27 pleomorphic adenoma 30.7 TP53 KRT14 ERBB2 CDKN2A
28 adenosquamous carcinoma 30.7 TP53 PGR KRT5 EGFR
29 apocrine adenocarcinoma 30.7 PGR KRT5 KRT14 ESR1 ERBB2
30 rare breast tumor 30.7 TP53 ESR1 ERBB2 BRCA2 BRCA1
31 serous cystadenocarcinoma 30.7 TP53 PGR ERBB2 BRCA2 BRCA1 AKT1
32 b-cell lymphoma 30.6 TP53 MIR17 CDKN2A CD44 CCND1
33 thyroid carcinoma 30.5 TP53 CDH1 AKT1
34 hypertrophy of breast 30.5 TP53 PGR ESR1 ERBB2 CYP19A1 BRCA2
35 skin carcinoma 30.5 TP53 PTGS2 EGFR CDKN2A CDH1 AKT1
36 wilms tumor 1 30.4 TP53 PGR ESR1 ERBB2 EGFR CDH1
37 adenocarcinoma 30.2 TP53 PTGS2 ERBB2 EGFR EGF CDKN2A
38 lymphoma 30.2 TP53 EGFR CDKN2A CDH1 CD44 CCND1
39 sporadic breast cancer 30.1 TP53 PGR ESR1 ERBB2 EGFR CYP19A1
40 breast carcinoma in situ 30.0 TP53 S100A7 PGR MIR17 KRT5 KRT14
41 breast cancer 30.0 TP53 S100A7 PTGS2 PGR MIR17 KRT5
42 adult t-cell leukemia 29.9 TP53 CDKN2A AKT1
43 squamous cell carcinoma 29.9 TP53 S100A7 PTGS2 ERBB2 EGFR EGF
44 endometrial cancer 29.8 TP53 PGR ESR1 ERBB2 EGFR EGF
45 renal cell carcinoma, nonpapillary 29.8 TP53 MIR17 EGFR EGF CLDN7 CDH1
46 hepatocellular carcinoma 29.3 TP53 PTGS2 MIR17 ESR1 ERBB2 EGFR
47 lung cancer 29.0 TP53 PTGS2 PGR MIR17 ESR1 ERBB2
48 prostate cancer 28.6 TP53 PTGS2 PGR MIR17 KRT5 ESR1
49 breast apocrine carcinoma in situ 11.4
50 bartholin's gland adenoid cystic carcinoma 10.8 PGR ESR1

Graphical network of the top 20 diseases related to Ductal Carcinoma in Situ:



Diseases related to Ductal Carcinoma in Situ

Symptoms & Phenotypes for Ductal Carcinoma in Situ

GenomeRNAi Phenotypes related to Ductal Carcinoma in Situ according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.26 EGFR
2 Decreased viability GR00221-A-1 10.26 AKT1 CDH1 CDKN2A EGFR ESR1
3 Decreased viability GR00221-A-2 10.26 AKT1 ESR1
4 Decreased viability GR00221-A-3 10.26 AKT1 CDKN2A ERBB2
5 Decreased viability GR00221-A-4 10.26 AKT1 CDKN2A EGFR ESR1 ERBB2
6 Decreased viability GR00301-A 10.26 CDH1
7 Decreased viability GR00402-S-2 10.26 AKT1 CDH1 CDKN2A EGFR ESR1 ERBB2
8 Decreased viability in esophageal squamous lineage GR00235-A 9.36 BRCA1 BRCA2 CCND1 CD44 CDH1 CDKN2A

MGI Mouse Phenotypes related to Ductal Carcinoma in Situ:

45 (show all 26)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.51 AKT1 BRCA1 BRCA2 CCND1 CD44 CDH1
2 integument MP:0010771 10.5 AKT1 BRCA1 BRCA2 CCND1 CD44 CDH1
3 cellular MP:0005384 10.49 AKT1 BRCA1 BRCA2 CCND1 CD44 CDH1
4 endocrine/exocrine gland MP:0005379 10.49 AKT1 BRCA1 BRCA2 CCND1 CD44 CDH1
5 digestive/alimentary MP:0005381 10.48 BRCA1 BRCA2 CCND1 CD44 CDH1 CDKN2A
6 homeostasis/metabolism MP:0005376 10.47 AKT1 BRCA1 BRCA2 CCND1 CD44 CDH1
7 behavior/neurological MP:0005386 10.44 AKT1 BRCA1 BRCA2 CCND1 CD44 CDKN2A
8 cardiovascular system MP:0005385 10.43 AKT1 BRCA1 CCND1 CD44 CDH1 CDKN2A
9 immune system MP:0005387 10.43 AKT1 BRCA1 BRCA2 CCND1 CD44 CDH1
10 hematopoietic system MP:0005397 10.42 AKT1 BRCA1 BRCA2 CCND1 CD44 CDKN2A
11 mortality/aging MP:0010768 10.41 AKT1 BRCA1 BRCA2 CCND1 CD44 CDH1
12 embryo MP:0005380 10.34 AKT1 BRCA1 BRCA2 CDH1 CDKN2A EGFR
13 neoplasm MP:0002006 10.32 AKT1 BRCA1 BRCA2 CCND1 CD44 CDH1
14 normal MP:0002873 10.25 AKT1 BRCA1 BRCA2 CCND1 CD44 CDH1
15 muscle MP:0005369 10.24 AKT1 BRCA1 CD44 CDKN2A CYP19A1 EGFR
16 adipose tissue MP:0005375 10.23 AKT1 BRCA1 CYP19A1 EGFR ESR1 KRT14
17 nervous system MP:0003631 10.23 AKT1 BRCA1 BRCA2 CCND1 CD44 CDKN2A
18 limbs/digits/tail MP:0005371 10.19 BRCA1 BRCA2 CD44 EGFR ERBB2 ESR1
19 reproductive system MP:0005389 10.16 AKT1 BRCA1 BRCA2 CCND1 CD44 CDH1
20 liver/biliary system MP:0005370 10.13 AKT1 CD44 CDKN2A CYP19A1 EGFR ESR1
21 no phenotypic analysis MP:0003012 10.03 CDH1 CDKN2A EGFR ESR1 KRT5 PGR
22 renal/urinary system MP:0005367 9.92 BRCA1 CD44 CLDN7 CYP19A1 EGFR ESR1
23 pigmentation MP:0001186 9.91 BRCA1 CD44 CDKN2A CYP19A1 EGFR KRT14
24 respiratory system MP:0005388 9.9 AKT1 BRCA1 CCND1 CD44 CDKN2A EGFR
25 skeleton MP:0005390 9.77 AKT1 BRCA1 BRCA2 CCND1 CD44 CDKN2A
26 vision/eye MP:0005391 9.28 CCND1 CD44 CDKN2A CYP19A1 EGF EGFR

Drugs & Therapeutics for Ductal Carcinoma in Situ

Drugs for Ductal Carcinoma in Situ (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 135)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Letrozole Approved, Investigational Phase 3 112809-51-5 3902
2
mometasone furoate Approved, Investigational, Vet_approved Phase 3 83919-23-7
3
Medroxyprogesterone acetate Approved, Investigational Phase 3 71-58-9
4
Tamoxifen Approved Phase 3 10540-29-1 2733526
5
Sodium citrate Approved, Investigational Phase 3 68-04-2
6
Trastuzumab Approved, Investigational Phase 3 180288-69-1 9903
7
Progesterone Approved, Vet_approved Phase 3 57-83-0 5994
8
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
9
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
10
Triamcinolone Approved, Vet_approved Phase 3 124-94-7 31307
11
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
12
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
13
Daunorubicin Approved Phase 3 20830-81-3 30323
14
Citric acid Approved, Nutraceutical, Vet_approved Phase 3 77-92-9 311
15
Emodepside Investigational, Vet_approved Phase 3 155030-63-0
16 Anti-Allergic Agents Phase 3
17 Contraceptive Agents Phase 3
18 Contraceptives, Oral Phase 3
19
Medroxyprogesterone Phase 3 520-85-4 10631
20 Contraceptive Agents, Male Phase 3
21 Estrogens Phase 3
22 Aromatase Inhibitors Phase 3
23 Selective Estrogen Receptor Modulators Phase 3
24 Citrate Phase 3
25 Hormone Antagonists Phase 3
26 Estrogen Receptor Antagonists Phase 3
27 Estrogen Antagonists Phase 3
28 Steroid Synthesis Inhibitors Phase 3
29 Antineoplastic Agents, Hormonal Phase 3
30 Estrogen Receptor Modulators Phase 3
31 Antineoplastic Agents, Immunological Phase 3
32 Immunologic Factors Phase 3
33 Antibodies, Monoclonal Phase 3
34 Immunoglobulins Phase 3
35 Antibodies Phase 3
36 Antirheumatic Agents Phase 3
37 Anti-Bacterial Agents Phase 3
38 Antibiotics, Antitubercular Phase 3
39 Topoisomerase Inhibitors Phase 3
40
Liposomal doxorubicin Phase 3 31703
41 Alkylating Agents Phase 3
42 Antimitotic Agents Phase 3
43 Immunosuppressive Agents Phase 3
44 Progestins Phase 3
45 Albumin-Bound Paclitaxel Phase 3
46 Triamcinolone diacetate Phase 3
47 Triamcinolone hexacetonide Phase 3
48 triamcinolone acetonide Phase 3
49 Chelating Agents Phase 3
50 Anticoagulants Phase 3

Interventional clinical trials:

(show top 50) (show all 167)
# Name Status NCT ID Phase Drugs
1 Interstitial Brachytherapy Alone Versus External Beam Radiation Therapy After Breast Conserving Surgery for Low-risk Invasive Carcinoma and Low-risk Ductal Carcinoma in Situ (DCIS) of the Female Breast Unknown status NCT00402519 Phase 3
2 Evaluation of the Diagnostic Performance of MRI±Biopsy to Optimize Resection of Ductal Carcinoma In Situ (DCIS) Breast Cancer Completed NCT01112254 Phase 3
3 A Clinical Trial Comparing Anastrozole With Tamoxifen in Postmenopausal Patients With Ductal Carcinoma in Situ (DCIS) Undergoing Lumpectomy With Radiation Therapy Completed NCT00053898 Phase 3 anastrozole;tamoxifen citrate
4 Phase III Randomized Double-Blind Study of Mometasone Furoate Versus Placebo in the Prevention of Radiation Dermatitis in Breast Cancer Patients Receiving Radiation Therapy Completed NCT00438659 Phase 3 mometasone furoate
5 Genetic Counseling for Newly Diagnosed Breast Cancer Patients Completed NCT00262899 Phase 3
6 A Phase III Prospective, Randomized, Double-Blind Clinical Trial of Hormone Replacement Therapy In Postmenopausal Women With A History Of Node-Negative Or Ductal Carcinoma In Situ Who Are Receiving Adjuvant Tamoxifen Completed NCT00026286 Phase 3 conjugated estrogens;medroxyprogesterone
7 Phase III Study in the Conservative Management of Breast Carcinoma by Tumorectomy and Radiotherapy: Assessment of the Role of a Booster Dose of Radiotherapy (Joint Study of the European Organisation for Research and Treatment of Cancer Radiotherapy Cooperative Group and Breast Cancer Cooperative Group) Completed NCT02295033 Phase 3
8 A Randomized Comparison Of Medroxyprogesterone Acetate (MA) And Observation For Prevention Of Endometrial Pathology In Postmenopausal Breast Cancer Patients Treated With Tamoxifen, Phase III Completed NCT00002920 Phase 3 medroxyprogesterone;tamoxifen citrate
9 A Phase III Randomized Double Blind Study of Letrozole Versus Placebo in Women With Primary Breast Cancer Completing Five or More Years of Adjuvant Tamoxifen Completed NCT00003140 Phase 3 letrozole
10 Evaluation of a New Intraoperative Gamma Camera for the Sentinel Lymph Node Procedure in Breast Cancer Completed NCT00757302 Phase 3
11 Prospective Randomized Study of Accelerated Radiation Therapy (PRART) Recruiting NCT04175210 Phase 3
12 Management of Low Risk Ductal Carcinoma in Situ (Low-risk DCIS): a Randomized, Multicentre, Non-inferiority Trial, Between Standard Therapy Approach Versus Active Surveillance Recruiting NCT02492607 Phase 3
13 Radiotherapy Versus Low-Dose Tamoxifen Following Breast Conserving Surgery for Low-Risk and Estrogen Receptor-Positive Ductal Carcinoma in Situ of Breast: an International Open-label Randomized Non-inferiority Trial Recruiting NCT04046159 Phase 3 Low-dose tamoxifen
14 International Breast Cancer Intervention Study II (IBIS-II) (DCIS) Active, not recruiting NCT00072462 Phase 3 tamoxifen citrate;Anastrozole
15 Phase III Trial of Tamoxifen Alone vs. Tamoxifen Plus Radiation Therapy for Good Risk Duct Carcinoma In-Situ (DCIS) of the Female Breast Active, not recruiting NCT00003857 Phase 3 tamoxifen citrate
16 A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently With Radiation Therapy and Radiation Therapy Alone for Women With HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy Active, not recruiting NCT00769379 Phase 3
17 A Multicentric Phase III Trial Evaluating the Impact of a Radiation Boost (16Gy) After Breast Conserving Surgery and a Whole Breast Irradiation (50Gy) for DCIS Active, not recruiting NCT00907868 Phase 3
18 A Randomised Phase III Study of Radiation Doses and Fractionation Schedules in Non-low Risk Ductal Carcinoma In Situ (DCIS) of the Breast Active, not recruiting NCT00470236 Phase 3
19 International Breast Cancer Intervention Study Active, not recruiting NCT00078832 Phase 3 anastrozole;placebo
20 A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer Active, not recruiting NCT01547741 Phase 3 Doxorubicin;Cyclophosphamide;Docetaxel;Paclitaxel
21 International Breast Cancer Intervention Study: A Multicentre Trial of Tamoxifen to Prevent Breast Cancer Active, not recruiting NCT00002644 Phase 3 Tamoxifen Citrate 20Mg Tab
22 A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer Active, not recruiting NCT01275677 Phase 3 Cyclophosphamide;Docetaxel;Doxorubicin;Doxorubicin Hydrochloride;Paclitaxel
23 Evaluation of the LightPath® Imaging System and the PET Tracer 68Ga-RM2 in Wide Local Excision (WLE) for Breast Cancer Not yet recruiting NCT03731026 Phase 3 68Ga-RM2
24 A Randomised, Double-Blind Trial to Assess the Effects on Bone Mineral Density and Bone Biomarkers of Anastrozole When Used to Prevent Breast Cancer in Postmenopausal Women Withdrawn NCT00324714 Phase 3 risedronate sodium
25 Randomised Trial Testing Observation (No Radiotherapy) Against Radiotherapy In Women With Low-Risk Completely Excised ER Positive Ductal Carcinoma In Situ (DCIS) Of The Breast On Adjuvant Endocrine Therapy Unknown status NCT00077168 Phase 2 anastrozole;tamoxifen citrate
26 A Phase II Randomized Study Of Intraductal Carboplatin In Women With Ductal Carcinoma In Situ Unknown status NCT00669747 Phase 2 Carboplatin i.d. Days 1 & 15;Carboplatin i.d. Day 1; Normal Saline i.d. Day 15;Normal Saline
27 Phase II Study - Dose Optimization PDR/HDR Brachytherapy Alone for Early Breast Cancer Unknown status NCT01175694 Phase 2
28 A Multicenter Phase II Study of Docosahexaenoic Acid (DHA) in Patients With a History of Breast Cancer, Premalignant Lesions, or Benign Breast Disease Unknown status NCT01849250 Phase 2 Docosahexaenoic Acid
29 Cisplatin-monotherapy in the Treatment of BRCA1 Positive Breast Cancer Patients in Poland Unknown status NCT01630226 Phase 2 Neoadjuvant Cisplatin Chemotherapy
30 Sulforaphane: A Dietary Histone Deacetylase (HDAC) Inhibitor in Ductal Carcinoma in Situ (DCIS) Completed NCT00843167 Phase 2
31 A Trial Assessing the Effect of Simvastatin on the Pharmacokinetics of Anastrozole Completed NCT00354640 Phase 2 anastrozole;simvastatin
32 Ten Years Results of a Score System to Address Adjuvant Therapies After Breast Conserving Surgery for Ductal Carcinoma in Situ of the Breast. Completed NCT03002766 Phase 2
33 A Phase II Study of Simvastatin in Women at High Risk for a New Breast Cancer Completed NCT00334542 Phase 2 simvastatin
34 Randomized Phase II Biomarker Pilot Trial of Fluvastatin Use in Women With Ductal Carcinoma in Situ (DCIS) or Stage I Breast Cancer Completed NCT00416403 Phase 2 fluvastatin sodium
35 MammoSite Radiation Therapy System (RTS) as the Sole Radiation Therapy Technique for Ductal Carcinoma In-Situ (DCIS) Completed NCT00586326 Phase 2
36 Intraoperative Radiation Therapy to the Tumor Bed for Boost Treatment After Lumpectomy Prior to Whole Breast Radiation in Breast Conservation Candidates Completed NCT00054301 Phase 2
37 Surrogate Markers of Response: A Phase II Study of Changes in Breast Density Among Postmenopausal Women Receiving Adjuvant Anastrozole Therapy Completed NCT00244959 Phase 2 anastrozole
38 Preventing Invasive Breast Neoplasia With Chloroquine (PINC) Trial Completed NCT01023477 Phase 1, Phase 2 Chloroquine Standard Dose (500mg/week);Chloroquine Low Dose (250mg/week)
39 Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS) Completed NCT01439711 Phase 2 letrozole
40 Phase II Clinical Trial of N-(4-hydroxyphenyl) Retinamide (4-HPR) and Tamoxifen in Breast Neoplasia, Administration During the Period Between the Diagnostic Core Biopsy and Definitive Surgery Completed NCT00003099 Phase 2 Fenretinide;Tamoxifen Citrate
41 Naltrexone Randomized Controlled Trial for Treatment-Emergent Fatigue in Patients Receiving Radiation Therapy for Breast Cancer Completed NCT02137252 Phase 2 Naltrexone;Sugar Pill
42 Phase II Trial of Docetaxel and Carboplatin Administered Every Two Weeks as Induction Therapy for Stage II or III Breast Cancer Completed NCT00107510 Phase 2 carboplatin;docetaxel
43 A Phase II Prospective Pilot Study Evaluating Efficacy of Intravenous Zoledronic Acid Prophylaxis for Prevention of Aromatase Inhibitor Associated Musculoskeletal Symptoms: ZAP-AIMSS Trial Completed NCT01194440 Phase 2 letrozole;zoledronic acid
44 Pre-surgical Phase IIb Trial of Transdermal 4-Hydroxytamoxifen vs. Oral Tamoxifen in Women With Ductal Carcinoma in Situ of the Breast Completed NCT00952731 Phase 2 oral placebo;afimoxifene;tamoxifen citrate;placebo gel
45 Validating CYP2D6 Genotype-Guided Tamoxifen Therapy for a Multiracial U.S. Population Completed NCT00764322 Phase 2 tamoxifen citrate
46 Phase II Chemoprevention Trial - Anastrozole in the DCIS and Early Invasive Breast Cancer in Postmenopausal Women Completed NCT00256217 Phase 2 Anastrozole
47 A Trial of Exemestane in Postmenopausal Women With DCIS or at High Risk for Invasive Breast Cancer Completed NCT00073073 Phase 2 Exemestane
48 A Phase IB Trial of Neoadjuvant Multi-epitope HER2 Peptide Vaccine in Patients With HER2-expressing DCIS Recruiting NCT03793829 Phase 1, Phase 2
49 TBCRC 042 - A Randomized Phase II Window-of-Opportunity Trial of Ruxolitinib in Patients With High Risk and Premalignant Breast Conditions Recruiting NCT02928978 Phase 2 Ruxolitinib;Placebo (for Ruxolitinib)
50 Preoperative Palbociclib in Patients With DCIS of the Breast That Are Candidates for Surgery Recruiting NCT03535506 Phase 2 Palbociclib

Search NIH Clinical Center for Ductal Carcinoma in Situ

Genetic Tests for Ductal Carcinoma in Situ

Genetic tests related to Ductal Carcinoma in Situ:

# Genetic test Affiliating Genes
1 Ductal Carcinoma in Situ 29

Anatomical Context for Ductal Carcinoma in Situ

MalaCards organs/tissues related to Ductal Carcinoma in Situ:

40
Breast, Lymph Node, Skin, Testes, Bone, Lung, Salivary Gland

Publications for Ductal Carcinoma in Situ

Articles related to Ductal Carcinoma in Situ:

(show top 50) (show all 6557)
# Title Authors PMID Year
1
A retrospective alternative for active surveillance trials for ductal carcinoma in situ of the breast. 61
31018242 2020
2
Risk factors for ductal carcinoma in situ of the breast in the UK Biobank cohort study. 61
31837535 2020
3
Ductal carcinoma in situ of the breast: immune cell composition according to subtype. 61
31375764 2020
4
Recommendations to improve patient-centred care for ductal carcinoma in situ: Qualitative focus groups with women. 61
31532871 2020
5
Prognostic significance of cathepsin V (CTSV/CTSL2) in breast ductal carcinoma in situ. 61
31444238 2020
6
Commentary: Creating a patient-centered decision aid for ductal carcinoma in situ. 61
32034829 2020
7
Low-Grade Ductal Carcinoma In Situ. 61
31769792 2020
8
Risk factors for estrogen receptor positive ductal carcinoma in situ of the breast in African American women. 61
31786415 2020
9
Non-mass versus mass-like ultrasound patterns in ductal carcinoma in situ: is there an association with high-risk histology? 61
31739979 2020
10
Breast magnetic resonance imaging for estimation of the tumour extent in patients with pure ductal carcinoma in situ: Comparison between full diagnostic and abbreviated protocols. 61
31874302 2020
11
High consistency between characteristics of primary intraductal breast cancer and subtype of subsequent ipsilateral invasive cancer. 61
31446852 2020
12
Giant cell tumor of soft tissue of the breast: Case report with H3F3A mutation analysis and review of the literature. 61
31784095 2020
13
Understanding the histogenesis of a HRAS-PIK3R1 co-driven metastatic metaplastic breast carcinoma associated with squamous metaplasia of lactiferous ducts. 61
31867792 2020
14
Microarray and RNA in situ hybridization assay for recurrence risk markers of breast carcinoma and ductal carcinoma in situ: Evidence supporting the use of diverse pathways panels. 61
31595577 2020
15
Preoperative assessment of breast cancer: Multireader comparison of contrast-enhanced MRI versus the combination of unenhanced MRI and digital breast tomosynthesis. 61
31838292 2020
16
Flat Epithelial Atypia in Breast Core Needle Biopsies With Radiologic-Pathologic Concordance: Is Excision Necessary? 61
31609784 2020
17
Increase in Utilization of Nipple-Sparing Mastectomy for Breast Cancer: Indications, Complications, and Oncologic Outcomes. 61
31823173 2020
18
Preoperative Delays in the Treatment of DCIS and the Associated Incidence of Invasive Breast Cancer. 61
31562602 2020
19
Do Body Mass Index and Breast Density Impact Cancer Risk Among Women with Lobular Carcinoma In Situ? 61
31898097 2020
20
Higher density of stromal M2 macrophages in breast ductal carcinoma in situ predicts recurrence. 61
31897820 2020
21
A quantitative centrosomal amplification score predicts local recurrence in ductal carcinoma in situ. 61
31937618 2020
22
Intracapsular High-Grade Ductal Carcinoma In-Situ Ex Pleomorphic Adenoma of the Lacrimal Gland. 61
31743286 2020
23
Pure Ductal Carcinoma in Situ in The Male Breast: A Rare Entity. 61
31912019 2020
24
Identification of aberrant gene expression during breast ductal carcinoma in situ progression to invasive ductal carcinoma. 61
30712460 2020
25
Clinic-Pathological Features of Breast Ductal Carcinoma in Situ with Micro-Invasion. 61
31939679 2020
26
Characteristics of ultrasonographic images of ductal carcinoma in situ with abnormalities of the ducts. 61
31655940 2020
27
Analysis of active surveillance as a treatment modality in ductal carcinoma in situ. 61
31925857 2020
28
Sentinel lymph node positivity in patients undergoing mastectomies for ductal carcinoma in situ (DCIS). 61
31957944 2020
29
Artifactual Displacement of Ductal Carcinoma In Situ (ADDCIS) (Toothpaste Effect): A Mimicker of Invasive Ductal Carcinoma. 61
31503011 2020
30
International comparison of cosmetic outcomes of breast conserving surgery and radiation therapy for women with ductal carcinoma in situ of the breast. 61
31431385 2020
31
Can dedicated breast PET help to reduce overdiagnosis and overtreatment by differentiating between indolent and potentially aggressive ductal carcinoma in situ? 61
31375867 2020
32
Multicentre study of the risk of invasive cancer and use of sentinel node biopsy in women with a preoperative diagnosis of ductal carcinoma in situ. 61
31823362 2020
33
ASO Author Reflections: Is Sentinel Lymph Node Biopsy Necessary in Patients with Ductal Carcinoma In Situ with Microinvasion Diagnosed on Core Biopsy? 61
31916089 2020
34
Metaplastic (adenosquamous) carcinoma in a phyllodes tumor with osseous metaplasia and ductal carcinoma in situ: A diagnostic challenge on core biopsy. 61
31909550 2020
35
Atypical Ductal Hyperplasia and Those Bordering on Ductal Carcinoma In Situ Should Be Included in the Active Surveillance Clinical Trials. 61
31602455 2020
36
Application of Contrast-Enhanced Ultrasound in the Diagnosis of Ductal Carcinoma In Situ: Analysis of 127 Cases. 61
31206200 2020
37
Recurrence Outcomes After Nipple-Sparing Mastectomy and Immediate Breast Reconstruction in Patients with Pure Ductal Carcinoma In Situ. 61
31912259 2020
38
Prognostic and predictive value of cell cycle progression (CCP) score in ductal carcinoma in situ of the breast. 61
31925342 2020
39
Phyllodes Tumor of the Breast: A Clinicopathological Evaluation of 55 Cases. 61
31912011 2020
40
Upgrade rate of intraductal papilloma without atypia on breast core needle biopsy: A clinical, radiological and pathological correlation study. 61
32007236 2020
41
Intracystic papillary carcinoma of the male breast: Dilemmas in diagnosis and management. 61
32039836 2020
42
Evaluating the role of sentinel lymph node biopsy in patients with DCIS treated with breast conserving surgery. 61
31964523 2020
43
Long noncoding RNA BHLHE40-AS1 promotes early breast cancer progression through modulating IL-6/STAT3 signaling. 61
31907974 2020
44
The number of FoxP3-positive tumor-infiltrating lymphocytes in patients with synchronous bilateral breast cancer. 61
31933123 2020
45
Loss of ANCO1 repression at AIB1/YAP targets drives breast cancer progression. 61
31788936 2020
46
In situ DESI - MSI lipidomic profiles of breast cancer molecular subtypes and precursor lesions. 61
31911556 2020
47
An alternative to standard lumpectomy: a 5-year case series review of oncoplastic breast surgery outcomes in a Canadian setting 61
31995336 2020
48
Recall and Outcome of Screen-detected Microcalcifications during 2 Decades of Mammography Screening in the Netherlands National Breast Screening Program. 61
31990268 2020
49
The prognostic significance of wild-type isocitrate dehydrogenase 2 (IDH2) in breast cancer. 61
31599393 2020
50
Metaplastic Carcinoma of the Breast: Analysis of 38 Cases from a Single Institute. 61
31769499 2020

Variations for Ductal Carcinoma in Situ

Cosmic variations for Ductal Carcinoma in Situ:

9 (show top 50) (show all 369)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM149317650 ZFHX3 breast,NS,carcinoma in situ,ductal carcinoma in situ c.2403A>T p.K801N 16:72957743-72957743 6
2 COSM87900157 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.818G>T p.R273L 17:7673802-7673802 6
3 COSM87898709 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.742C>T p.R248W 17:7674221-7674221 6
4 COSM87899395 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.824G>T p.C275F 17:7673796-7673796 6
5 COSM87899661 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.797G>A p.G266E 17:7673823-7673823 6
6 COSM87906851 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.836G>A p.G279E 17:7673784-7673784 6
7 COSM87906185 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.517G>T p.V173L 17:7675095-7675095 6
8 COSM87990558 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.860A>G p.E287G 17:7673760-7673760 6
9 COSM87897711 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.818G>A p.R273H 17:7673802-7673802 6
10 COSM87943620 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.711G>C p.M237I 17:7674252-7674252 6
11 COSM87898578 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.733G>A p.G245S 17:7674230-7674230 6
12 COSM87915191 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.532C>G p.H178D 17:7675080-7675080 6
13 COSM87899842 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.584T>C p.I195T 17:7674947-7674947 6
14 COSM87898351 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.743G>A p.R248Q 17:7674220-7674220 6
15 COSM87907089 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.587G>C p.R196P 17:7674944-7674944 6
16 COSM89652676 SMARCA4 breast,NS,carcinoma in situ,ductal carcinoma in situ c.1111G>T p.E371* 19:10987917-10987917 6
17 COSM91776956 PPP2R1A breast,NS,carcinoma in situ,ductal carcinoma in situ c.510C>A p.F170L 19:52212692-52212692 6
18 COSM87132272 PIK3CA breast,NS,carcinoma in situ,ductal carcinoma in situ c.1634A>C p.E545A 3:179218304-179218304 6
19 COSM87132245 PIK3CA breast,NS,carcinoma in situ,ductal carcinoma in situ c.3140A>G p.H1047R 3:179234297-179234297 6
20 COSM87132454 PIK3CA breast,NS,carcinoma in situ,ductal carcinoma in situ c.3140A>T p.H1047L 3:179234297-179234297 6
21 COSM87132301 PIK3CA breast,NS,carcinoma in situ,ductal carcinoma in situ c.1624G>A p.E542K 3:179218294-179218294 6
22 COSM87134467 PIK3CA breast,NS,carcinoma in situ,ductal carcinoma in situ c.3139C>T p.H1047Y 3:179234296-179234296 6
23 COSM87132308 PIK3CA breast,NS,carcinoma in situ,ductal carcinoma in situ c.1633G>A p.E545K 3:179218303-179218303 6
24 COSM87132330 PIK3CA breast,NS,carcinoma in situ,ductal carcinoma in situ c.1035T>A p.N345K 3:179203765-179203765 6
25 COSM97107777 NRAS breast,NS,carcinoma in situ,ductal carcinoma in situ c.35G>C p.G12A 1:114716126-114716126 6
26 COSM97107326 NRAS breast,NS,carcinoma in situ,ductal carcinoma in situ c.181C>A p.Q61K 1:114713909-114713909 6
27 COSM87645669 NOTCH1 breast,NS,carcinoma in situ,ductal carcinoma in situ c.7372C>T p.P2458S 9:136496367-136496367 6
28 COSM101146280 MYCL breast,NS,carcinoma in situ,ductal carcinoma in situ c.659C>T p.T220M 1:39897898-39897898 6
29 COSM85396421 MAP2K2 breast,NS,carcinoma in situ,ductal carcinoma in situ c.931G>T p.D311Y 19:4097332-4097332 6
30 COSM87804005 KRAS breast,NS,carcinoma in situ,ductal carcinoma in situ c.35G>A p.G12D 12:25245350-25245350 6
31 COSM87804075 KRAS breast,NS,carcinoma in situ,ductal carcinoma in situ c.34G>T p.G12C 12:25245351-25245351 6
32 COSM87804055 KRAS breast,NS,carcinoma in situ,ductal carcinoma in situ c.35G>T p.G12V 12:25245350-25245350 6
33 COSM87804028 KRAS breast,NS,carcinoma in situ,ductal carcinoma in situ c.38G>A p.G13D 12:25245347-25245347 6
34 COSM88386447 KMT2C breast,NS,carcinoma in situ,ductal carcinoma in situ c.925C>T p.P309S 7:152273792-152273792 6
35 COSM88397801 KMT2C breast,NS,carcinoma in situ,ductal carcinoma in situ c.2681G>A p.R894Q 7:152235905-152235905 6
36 COSM112989732 HRAS breast,NS,carcinoma in situ,ductal carcinoma in situ c.148A>G p.T50A 11:533908-533908 6
37 COSM95516872 H3-3A breast,NS,carcinoma in situ,ductal carcinoma in situ c.218G>A p.R73Q 1:226065745-226065745 6
38 COSM88586406 ERBB2 breast,NS,carcinoma in situ,ductal carcinoma in situ c.2264T>C p.L755S 17:39723967-39723967 6
39 COSM88585849 ERBB2 breast,NS,carcinoma in situ,ductal carcinoma in situ c.929C>T p.S310F 17:39711955-39711955 6
40 COSM87756352 CDH1 breast,NS,carcinoma in situ,ductal carcinoma in situ c.779C>T p.P260L 16:68810288-68810288 6
41 COSM133536627 AKT1 breast,NS,carcinoma in situ,ductal carcinoma in situ c.61A>G p.T21A 14:104780202-104780202 6
42 COSM133535772 AKT1 breast,NS,carcinoma in situ,ductal carcinoma in situ c.49G>A p.E17K 14:104780214-104780214 6
43 COSM145165829 breast,NS,carcinoma in situ,ductal carcinoma in situ c.779C>T p.P260L 16:68810288-68810288 6
44 COSM143944147 breast,NS,carcinoma in situ,ductal carcinoma in situ c.265C>T p.R89W 17:7674221-7674221 6
45 COSM112254852 breast,NS,carcinoma in situ,ductal carcinoma in situ c.584T>C p.I195T 17:7674947-7674947 6
46 COSM148932677 breast,NS,carcinoma in situ,ductal carcinoma in situ c.1634A>C p.E545A 3:179218304-179218304 6
47 COSM122733862 breast,NS,carcinoma in situ,ductal carcinoma in situ c.422G>A p.R141H 17:7673802-7673802 6
48 COSM144092525 breast,NS,carcinoma in situ,ductal carcinoma in situ c.110G>C p.R37P 17:7674944-7674944 6
49 COSM112253807 breast,NS,carcinoma in situ,ductal carcinoma in situ c.733G>A p.G245S 17:7674230-7674230 6
50 COSM91859716 breast,NS,carcinoma in situ,ductal carcinoma in situ c.35G>A p.G12D 12:25245350-25245350 6

Expression for Ductal Carcinoma in Situ

Search GEO for disease gene expression data for Ductal Carcinoma in Situ.

Pathways for Ductal Carcinoma in Situ

Pathways related to Ductal Carcinoma in Situ according to GeneCards Suite gene sharing:

(show top 50) (show all 85)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.86 TP53 PTGS2 ESR1 ERBB2 EGFR EGF
2
Show member pathways
13.72 TP53 PTGS2 ESR1 ERBB2 EGFR EGF
3
Show member pathways
13.42 TP53 PTGS2 ERBB2 EGFR EGF CD44
4
Show member pathways
13.17 TP53 EGFR EGF CLDN7 CCND1 AKT1
5
Show member pathways
13 TP53 PTGS2 EGFR CDKN2A CCND1 AKT1
6
Show member pathways
13 TP53 PTGS2 ERBB2 EGFR EGF CCND1
7
Show member pathways
12.96 PTGS2 ERBB2 EGFR EGF CCND1 AKT1
8
Show member pathways
12.89 TP53 ERBB2 EGFR EGF CDKN2A CDH1
9 12.82 TP53 ERBB2 EGFR EGF AKT1
10
Show member pathways
12.79 TP53 ERBB2 EGFR EGF AKT1
11
Show member pathways
12.77 TP53 PTGS2 ESR1 ERBB2 CDH1 AKT1
12
Show member pathways
12.76 TP53 ESR1 CCND1 BRCA2 BRCA1
13
Show member pathways
12.74 PGR KRT14 ESR1 EGFR AKT1
14 12.72 TP53 PTGS2 ESR1 ERBB2 EGFR EGF
15
Show member pathways
12.67 TP53 ERBB2 EGFR EGF CCND1 AKT1
16 12.57 TP53 CDKN2A CCND1 BRCA2 BRCA1
17
Show member pathways
12.55 TP53 ERBB2 EGFR EGF CDH1 AKT1
18 12.51 TP53 PTGS2 MIR17 ERBB2 EGFR CDKN2A
19
Show member pathways
12.49 TP53 ESR1 ERBB2 EGFR EGF CDKN2A
20 12.48 TP53 PTGS2 CDH1 CCND1 AKT1
21
Show member pathways
12.46 PTGS2 ESR1 CD44 BRCA1 AKT1
22
Show member pathways
12.44 TP53 MIR17 CDKN2A CCND1 BRCA1
23 12.43 TP53 EGFR CD44 AKT1
24 12.42 TP53 CDKN2A CDH1 CCND1
25
Show member pathways
12.41 EGFR EGF CCND1 AKT1
26 12.4 TP53 CDKN2A CCND1 AKT1
27
Show member pathways
12.38 PTGS2 ESR1 ERBB2 EGFR EGF CCND1
28
Show member pathways
12.35 ERBB2 EGFR EGF AKT1
29 12.33 TP53 ESR1 ERBB2 EGFR CD44 CCND1
30
Show member pathways
12.32 TP53 CCND1 BRCA1 AKT1
31
Show member pathways
12.29 TP53 ERBB2 EGFR CCND1 AKT1
32
Show member pathways
12.28 PGR ESR1 CDKN2A CCND1 BRCA1
33 12.25 ERBB2 EGFR EGF AKT1
34 12.24 TP53 CDKN2A CCND1 AKT1
35
Show member pathways
12.2 ERBB2 EGFR EGF AKT1
36 12.19 TP53 PTGS2 EGFR EGF CDH1 CCND1
37
Show member pathways
12.18 ERBB2 EGFR EGF CCND1 AKT1
38
Show member pathways
12.15 EGFR EGF CCND1 AKT1
39
Show member pathways
12.11 ERBB2 EGFR EGF CCND1 AKT1
40
Show member pathways
12.09 TP53 ERBB2 EGFR AKT1
41 12.08 TP53 PTGS2 EGFR CCND1
42 12.07 TP53 ESR1 CCND1 AKT1
43
Show member pathways
12.07 TP53 PGR ESR1 ERBB2 EGFR EGF
44 12.05 TP53 EGFR EGF CDKN2A CCND1 AKT1
45 12.04 TP53 PTGS2 CCND1 AKT1
46 12.04 TP53 ERBB2 CDKN2A CCND1 AKT1
47 12.01 EGFR EGF CDH1 AKT1
48 12.01 ERBB2 EGFR EGF AKT1
49
Show member pathways
11.99 PGR ESR1 ERBB2 EGFR EGF
50 11.93 TP53 PTGS2 CCND1 AKT1

GO Terms for Ductal Carcinoma in Situ

Cellular components related to Ductal Carcinoma in Situ according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 9.83 TP53 S100A7 PTGS2 PGR KRT5 KRT14
2 basolateral plasma membrane GO:0016323 9.46 ERBB2 EGFR CLDN7 CD44
3 protein-containing complex GO:0032991 9.17 TP53 PTGS2 ESR1 EGFR BRCA2 BRCA1

Biological processes related to Ductal Carcinoma in Situ according to GeneCards Suite gene sharing:

(show all 48)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.21 TP53 PGR ESR1 EGFR CDKN2A BRCA1
2 cellular response to DNA damage stimulus GO:0006974 10.1 TP53 CCND1 BRCA2 BRCA1 AKT1
3 negative regulation of apoptotic process GO:0043066 10.06 TP53 PTGS2 EGFR CLDN7 CD44 AKT1
4 cell proliferation GO:0008283 9.99 TP53 EGFR BRCA2 AKT1
5 regulation of cell proliferation GO:0042127 9.98 TP53 PTGS2 EGFR BRCA1
6 negative regulation of gene expression GO:0010629 9.97 TP53 PGR MIR17 ESR1 AKT1
7 positive regulation of gene expression GO:0010628 9.97 TP53 ERBB2 EGF CDKN2A BRCA1 AKT1
8 positive regulation of protein phosphorylation GO:0001934 9.96 ERBB2 EGFR CCND1 AKT1
9 positive regulation of protein kinase B signaling GO:0051897 9.95 ESR1 ERBB2 EGFR EGF
10 cellular response to hypoxia GO:0071456 9.9 TP53 PTGS2 MIR17 AKT1
11 response to oxidative stress GO:0006979 9.89 TP53 PTGS2 EGFR AKT1
12 cellular response to mechanical stimulus GO:0071260 9.87 PTGS2 EGFR AKT1
13 positive regulation of cell growth GO:0030307 9.87 ERBB2 EGFR AKT1
14 cellular response to growth factor stimulus GO:0071363 9.86 ERBB2 EGFR AKT1
15 double-strand break repair GO:0006302 9.86 TP53 BRCA2 BRCA1
16 positive regulation of epithelial cell proliferation GO:0050679 9.85 ERBB2 EGFR CCND1
17 response to estrogen GO:0043627 9.84 ESR1 CCND1 BRCA1
18 positive regulation of MAP kinase activity GO:0043406 9.84 ERBB2 EGFR EGF
19 positive regulation of smooth muscle cell proliferation GO:0048661 9.83 PTGS2 EGFR AKT1
20 response to estradiol GO:0032355 9.83 PTGS2 ESR1 EGFR CCND1
21 positive regulation of fibroblast proliferation GO:0048146 9.82 MIR17 ESR1 EGFR
22 epidermal growth factor receptor signaling pathway GO:0007173 9.82 EGFR EGF AKT1
23 epidermis development GO:0008544 9.81 S100A7 KRT5 KRT14 EGFR
24 positive regulation of G1/S transition of mitotic cell cycle GO:1900087 9.8 EGFR CCND1 AKT1
25 cellular response to epidermal growth factor stimulus GO:0071364 9.8 ERBB2 EGFR AKT1
26 positive regulation of cell proliferation GO:0008284 9.8 PTGS2 ERBB2 EGFR EGF CLDN7 CCND1
27 negative regulation of Notch signaling pathway GO:0045746 9.79 EGFR EGF AKT1
28 cellular response to reactive oxygen species GO:0034614 9.78 TP53 EGFR AKT1
29 response to organic substance GO:0010033 9.78 PTGS2 CDH1 CCND1 AKT1
30 positive regulation of vasoconstriction GO:0045907 9.75 PTGS2 EGFR AKT1
31 regulation of cell motility GO:2000145 9.73 ERBB2 EGFR EGF
32 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.73 PTGS2 EGFR CD44 AKT1
33 positive regulation of cyclin-dependent protein serine/threonine kinase activity GO:0045737 9.72 EGFR CCND1 AKT1
34 ERBB2 signaling pathway GO:0038128 9.71 ERBB2 EGFR EGF
35 negative regulation of cysteine-type endopeptidase activity involved in apoptotic process GO:0043154 9.71 PTGS2 MIR17 CD44 AKT1
36 positive regulation of RNA polymerase II transcriptional preinitiation complex assembly GO:0045899 9.7 TP53 ESR1
37 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.69 TP53 EGFR
38 negative regulation of production of miRNAs involved in gene silencing by miRNA GO:1903799 9.69 TP53 ESR1
39 mitotic G1 DNA damage checkpoint GO:0031571 9.68 TP53 CCND1
40 cellular response to indole-3-methanol GO:0071681 9.64 CDH1 BRCA1
41 negative regulation of immature T cell proliferation in thymus GO:0033088 9.63 ERBB2 CDKN2A
42 response to X-ray GO:0010165 9.63 TP53 CCND1 BRCA2
43 chordate embryonic development GO:0043009 9.61 BRCA2 BRCA1
44 mammary gland alveolus development GO:0060749 9.54 ESR1 EGF CCND1
45 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.5 TP53 BRCA2 BRCA1
46 negative regulation of ERBB signaling pathway GO:1901185 9.33 ERBB2 EGFR EGF
47 positive regulation of transcription, DNA-templated GO:0045893 9.28 TP53 ESR1 EGFR EGF CDKN2A CDH1
48 response to UV-A GO:0070141 9.13 EGFR CCND1 AKT1

Molecular functions related to Ductal Carcinoma in Situ according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.28 TP53 S100A7 PTGS2 PGR KRT5 KRT14
2 protein kinase binding GO:0019901 9.73 TP53 ESR1 EGFR CDKN2A CCND1 AKT1
3 identical protein binding GO:0042802 9.65 TP53 PGR ESR1 ERBB2 EGFR CLDN7
4 nitric-oxide synthase regulator activity GO:0030235 9.33 ESR1 EGFR AKT1
5 enzyme binding GO:0019899 9.23 TP53 PTGS2 PGR ESR1 EGFR CCND1

Sources for Ductal Carcinoma in Situ

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....